<DOC>
	<DOCNO>NCT01377961</DOCNO>
	<brief_summary>Type 2 diabetes mellitus ( DM2 ) grow social health problem world-wide , particular respect contribution cardiovascular disease . The progressive increase prevalence DM2 reach epidemic proportion major cause morbidity mortality population around world . Conventional stepwise treatment DM2 generally focus control blood glucose concentration . However , risk side-effects associate use pharmacological intervention often delay initiation therapy , potential implication worsen morbidity mortality complication . On hand , non-pharmacological intervention form dietary restriction , exercise weight loss , safe often difficult accomplish . The availability nutrient affect glucose lipid metabolism would provide important practical tool establish early intervention newly diagnose DM2 perhaps even patient `` risk '' DM2 . The investigator recently obtain preliminary data beneficial effect combine supplementation lycopene isoflavones glucose metabolism normoglycemic volunteer insulin resistance . This clinical trial explore role isoflavones lycopene dietary supplementation improvement glucose metabolism patient increase risk establish mild DM2 . The overall hypothesis supplementation laflavon , provide new formulation increase bioavailability individual component ( Laflavon CamMedica contain 7 mg Lycopene 50 mg Soy Isoflavones ) , determine improvement glucose tolerance insulin resistance patient metabolic syndrome also reduce HbA1c patient mild DM2 .</brief_summary>
	<brief_title>Effect Lycopene Isoflavones Glucose Metabolism</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Lycopene</mesh_term>
	<mesh_term>Carotenoids</mesh_term>
	<criteria>Study group 1 ( arm 1 : :metabolic syndrome group ) . Inclusion criterion : Age 1875 year Metabolic Syndrome ( IDF criterion ) Stable dose medication &gt; 90 day Exclusion criterion : Pharmacological therapy diabetes Flood allergy , especially Whey protein , soy tomato . Pregnancy Study group 2 ( Arm 2 : : Diabetes mellitus patient group ) . Inclusion criterion : 1875 year age Type 2 diabetes ( diagnose ADA criterion : fasting plasma glucose &gt; 125 mg/dL ) Stable dose medication &gt; 90 day Patients diet/exercise , metformin , DD4 inhibitor ( sitagliptin saxagliptin ) /or sulphonylurea &gt; 90 day Exclusion criterion : HbA1c 9.5 % 7.5 % last 3 month TZD therapy diabetes Insulin therapy diabetes Flood allergy , especially Whey protein , soy tomato Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>